Company profile
Glaukos Corporation
NYSE: GKOS · Healthcare · Medical - Devices
#210 of 1,422 Healthcare companies by revenue72nd-percentile growth
EA Score
71BFH 65DQ 84GM 59SS 78
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$551.3M
Rev growth YoY (TTM)
+36.3%
Net income (FY)
-$187.7M
Employees
1,094
as of 2026-08-06
Market cap
$10.1B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$507.4M$507.4M2025
Net income-$187.7M-$187.7M2025
Operating income-$199.6M-$199.6M2025
Total assets$893.5M$893.5M2025
Liabilities$237.3M$237.3M2025
Equity$656.2M$656.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Glaukos Corporation’s revenue?
Glaukos Corporation booked $507.4M in FY2025 revenue, growing 32% year over year — faster than most Healthcare companies we track, at a -37.0% net margin.
Peers · Healthcare
Veracyte, Inc.82B+Inotiv, Inc.63CADMA Biologics, Inc.85AThe Oncology Institute, Inc.52DBridgeBio Pharma, Inc.53DAscend Wellness Holdings, Inc.53DNeighbors
Orange →Key facts
CEOThomas William Burns
SectorHealthcare
IndustryMedical - Devices
HeadquartersAliso Viejo, CA
ExchangeNYSE: GKOS
Employees1,094
IPO date2015-06-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.